CRS is a significant challenge associated with CAR-T cell therapy, often resulting from the release of various interleukins (IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, etc.). The gene discussed is IL2; the disease is congenital rubella syndrome.